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Abstract
Purpose Sentinel lymph node biopsy (SLNB) was introduced as a minimally invasive technique for nodal staging. Since
associated morbidity is not negligible, it is highly relevant to pursue a more minimally invasive alternative. The purpose of this
study was to prospectively evaluate the sensitivity of fine needle aspiration cytology (FNAC) with combined gamma probe and
ultrasound (US) guidance in comparison with the gold standard histology of the sentinel node (SN) after SLNB for detecting
metastasis.
Methods The study was designed as a prospective, multicentre, open-label, single-arm trial enrolling patients with newly
diagnosed cutaneous melanoma or breast cancer betweenMay 2015 and August 2017. Sample radioactivity was measured using
a Mini 900 scintillation monitor. After FNAC, all patients underwent SLNB. Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were estimated.
Results Accrual was terminated early following an unplanned interim analysis indicating that a FNAC sensitivity of at least 80%
could not be achieved. In total 58 patients of the originally planned 116 patients underwent FNAC with gamma probe and US
guidance. There were no true-positive FNAC results, 14 false-negative results and one false-positive result, and thus the
sensitivity, specificity, PPV and NPVof FNAC were 0%, 98%, 0% and 75%, respectively. At least 75% of the FNAC samples
had a radioactivity signal higher than the background signal.
Conclusion FNAC with gamma probe and US guidance is not able to correctly detect metastases in the SN and is therefore not
able to replace SLNB. Gamma probe-guided US is a highly accurate method for correctly identifying the SN, which offers
possibilities for future research.
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Introduction
The sentinel lymph node biopsy (SLNB) procedure was intro-
duced in the early 1990s as a less-invasive technique than
elective lymph node dissection, enabling selective detection
and histopathological inspection of the primary draining
lymph node in the regional lymph node basin related to the
primary tumour site, e.g. melanoma or breast cancer [1, 2].
The status of the (sentinel) lymph nodes is one of the most
important prognostic indicators for recurrence and survival
[3–5]. In addition, (sentinel) lymph node status guides
locoregional treatment decisions and will probably soon guide
the choice of systemic treatment.
Although less invasive than elective lymph node dissec-
tion, the morbidity associated with SLNB is not negligible.
This is of particular concern since a positive sentinel node
(SN) is found in only 20–30% of patients [5–7]. Morbidity
occurs in approximately 11% of patients, with the most com-
mon early postoperative complications being seroma (about
5%) and infection (about 3%) [8]. Lymphoedema has been
reported to occur in at least 6% of patients [9, 10]. It is impor-
tant to note that SLNB does not improve survival but only
provides accurate and important staging information [5, 11].
In this light, it seems highly relevant to pursue a more mini-
mally invasive alternative to SLNB. Fine needle aspiration
cytology (FNAC) with ultrasound (US) guidancemay provide
a good minimally invasive alternative. Several studies have
focused on US examination with or without FNAC in mela-
noma patients, but sensitivity rates vary greatly and most stud-
ies lacked a method to accurately identify the SN prior to US
examination and FNAC [12]. This problem could be over-
come by using a hand-held gamma probe as an aid to US
identification of the SN after lymphoscintigraphy. This has
been shown to be feasible in several studies in breast cancer
patients, in which the SN was correctly identified in 75–100%
of patients [13–16].
The purpose of this study was to prospectively evaluate the
sensitivity of FNAC with combined gamma probe and US
guidance compared with the gold standard, histology of the
SN after SLNB, for detecting SN metastasis.
Materials and methods
Study design
Details of the study design and protocol have been published
previously [12]. Briefly, the trial was designed as a prospec-
tive, multicentre, open-label, single-arm trial and was per-
formed in two Dutch hospitals. The Ethical Review Board
approved the study protocol. This trial was registered with
The Netherlands Trial Registry (NTR; ID NRT5193, 1
May 2015). The study was prepared in accordance with the
Standards for Reporting of Diagnostic Accuracy Studies [17].
Participants
Patients with newly diagnosed cT1b-4N0M0 cutaneous mel-
anoma or cT1-3N0M0 breast cancer were recruited from
May 2015 to August 2017. Patients were excluded if they
were unwilling or unable to give informed consent, or if they
had a clinically suspicious lymph node, other known malig-
nancy with potential to disseminate to the axillary or groin
lymph node basins, prior lymph node biopsy, or no SN visible
on lymphoscintigraphy. All participants provided written in-
formed consent.
Procedures
After peritumoral or intradermal injection of 99mTc-
nanocolloid, lymphoscintigraphy was performed according
to the institution’s standard protocol during the 24 h before
surgery to define the location of the SN. A nuclear medicine
specialist reported information regarding the identified SN
basin(s) and primary tier SN(s). The presumed SN(s) were
distinguished from the second-tier nodes by visualization of
the first node or a direct drainage pathway. Following success-
ful lymphoscintigraphy, a dedicated radiologist identified the
hot spot over the skin using a hand-held gamma probe (16 mm
Europrobe 3) and the area was examined using US (Aloka
ProSound alpha10) with a 1–15 MHz linear transducer to
attempt to visualize the assumed SN (a visible lymph node
at the centre of the hotspot as identified with the gamma
probe; Fig. 1). Fine needle aspiration of all visualized assumed
SN(s) was performed using a 21-gauge needle, regardless of
suspicion of metastasis on US examination, with usually one
or two cortical samples per SN (depending on the visual yield
of each sample). A Mini 900 scintillation monitor with a so-
dium iodide crystal was used, when available, to measure
radioactivity of the samples. All FNAC samples were subse-
quently transported to and analysed in the pathology labora-
tory of the Erasmus MC Cancer Institute.
Cytological smears were prepared according to a standard
protocol. Cytomorphology was assessed on haematoxylin and
eosin (H&E) stained smears. The remainder of the aspirate
was expressed into a CytoLyt solution from which a Cellient
cell block was prepared, provided that an adequate amount of
material was obtained. Cytomorphology was assessed again.
In addition immunohistochemical staining was performed
using S-100 and Melan-A for melanoma samples and Ker8-
18 for breast cancer samples. US examination findings are
reported according to the Berlin morphological criteria [18].
The SN identified on US examination was regarded as malig-
nant when the lymph node appeared Bballoon shaped^, and
suspicious if peripheral perfusion, loss of central echoes,
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asymmetrical broadening of the parenchyma, or an echo-poor
island within an otherwise normal lymph node was present
[18, 19]. After FNAC, all patients proceeded directly to the
operating room for SLNB. The SNs were handled and
assessed in each centre according to the European
Organization for Research and Treatment of Cancer
(EORTC) SN pathology protocol [20].
Outcomes
The primary objective of the trial was to assess the sensitivity
of FNAC with combined gamma probe and US guidance in
detecting SN metastasis in patients with melanoma or breast
cancer. Prespecified secondary end-points evaluated in the
pilot phase of the study included the SN identification rate
and the histological results of core needle biopsy (CNB) in
comparison with FNAC and SLNB.
Statistical analysis
Power and sample size calculations are described in detail
elsewhere [12]. Considering a 30% prevalence, the required
sample size was 116 patients to detect metastatic SN(s) with a
sensitivity of 90% and a 95% confidence interval (CI) of 80–
100%, with a two-sided significance level α of 0.05 and a
power 1 − β of 0.80. The estimated recruitment goal was
120 patients.
Negative FNAC was defined as absence of metastatic tu-
mour cells (i.e. negative cytology) or unrepresentative cytol-
ogy due to collection of an insufficient number of cells. Based
on comparison with final histology, four types of FNAC re-
sults were defined: false-negative, true-negative, false-
positive and true-positive. The same definitions were applied
to the CNB results and the US results according to the Berlin
criteria. A malignant or suspicious SN on US examination
according to the Berlin criteria was recorded as positive.
Continuous data are presented as medians with interquar-
tile ranges (IQR) and categorical data as frequencies with their
respective percentages. The number of true-positives, false-
positives, false-negatives and true-negatives were calculated.
Positive predictive value, negative predictive value, specifici-
ty and sensitivity were estimated. When clinical data were
missing, the clinical characteristic was categorized as
Bunknown^. Two-sided P values <0.050 were considered sta-
tistically significant. SPSS version 22.0 (IBM, Armonk, NY)
was used for all statistical analyses.
Results
A total of 68 clinically node-negative patients with melanoma
or breast cancer were enrolled, of whom 10 (15%) did not
undergo FNAC and therefore were excluded from further
analysis (Fig. 2). Baseline characteristics of the 58 patients
who did undergo FNAC with combined gamma probe and
US guidance are shown in Table 1. The median number of
A
B
C
D
Fig. 1 Identification of the presumed sentinel node in the axilla (A) using
the ultrasound probe (B), gamma probe (C) and the skin mark (D)
Fig. 2 Selection of patients who
underwent FNAC with gamma
probe and US guidance
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identified SNs on lymphoscintigraphy was 1 (IQR 1–2) and
the median number of SN basins on lymphoscintigraphy was
1 (IQR 1–1). The median number of identified SNs on FNAC
with gamma probe and US guidance was 1 (IQR 1–2) and the
median number of retrieved SNs during SLNB was 2 (IQR 1–
3; P < 0.001).
Originally 116 patients were planned to be included. Slow
accrual prompted extension of the predefined study period,
but before this was done, an unplanned (non-protocol-speci-
fied) interim efficacy analysis was carried out. Evaluation of
the results indicated that even in the best case scenario a
FNAC sensitivity of at least 80% could not be achieved, and
accrual was therefore terminated. Early termination was not
related to any safety concerns related to FNAC with gamma
probe and US guidance. The interim analysis was performed
in July 2017 with available data on the first 53 patients who
had undergone FNAC (an additional five patients had been
included but data on these patients were not yet complete).
The technique was considered successful if a sensitivity of
90% with an upper and lower 95% CI of 80–100% was
achieved. Calculations based on the data available showed
that in the best-case scenario, the highest achievable sensitiv-
ity would be 63% (Supplementary material).
Results of FNAC with gamma probe and US guidance
The cytological smears were representative in 51 of 58 pa-
tients (88%) and additional cytomorphology and immunohis-
tochemistry analysis on Cellient blocks was possible in 39 of
58 patients (67%). In patients with insufficient cytology
FNAC was recorded as negative. One of these patients turned
out to have a positive SN on histology, and the FNAC result
was recorded as false-negative. The radioactivity signal of the
material, measured using the Mini 900 scintillation monitor
with a sodium iodide crystal, was reported to be more than
twice the background signal in 33 of the 44 tested samples
(75%).
The results of the FNAC, US examination (according to
the Berlin criteria) and CNB and measures of diagnostic
Table 1 Baseline characteristics of the 58 analysed patients and
tumours
Characteristic Value
Gender
Male 18 (31)
Female 40 (69)
Age (years) 56 (44–64)
Body mass index (kg/m2) 25.1 (22.4–27.1)
Breast cancer 21 (36)
Size (mm) 15.0 (6.5–28.3)
Side
Right 14 (67)
Left 7 (33)
Quadrant
Left upper 8 (38)
Left lower 3 (14)
Medial lower 3 (14)
Medial upper 4 (19)
Histology
Ductal 15 (71)
Other 6 (29)
Oestrogen receptor status
Negative 3 (14)
Positive 16 (76)
Unknown 2 (10)
Progesterone receptor status
Negative 5 (24)
Positive 14 (67)
Unknown 2 (10)
Her2neu status
Negative 15 (71)
Positive 4 (19)
Unknown 2 (10)
Melanoma 37 (63.8)
Breslow thickness (mm) 1.85 (1.13–4.00)
Location
Arm 8 (21.6)
Leg 14 (37.8)
Trunk 15 (40.5)
Histology
Superficial spreading 18 (48.6)
Nodular 10 (27.0)
Acral lentiginous 2 (5.4)
Lentigo maligna 2 (5.4)
Other 2 (5.4)
Unknown 3 (8.1)
Ulceration
Present 10 (27.0)
Absent 25 (67.6)
Unknown 2 (5.4)
Regression
Table 1 (continued)
Characteristic Value
Complete 1 (2.7)
Partial 2 (5.4)
Absent 32 (86.5)
Unknown 2 (5.4)
Micro satellites
Present 1 (2.7)
Absent 33 (89.2)
Unknown 3 (8.1)
The values presented are number (%) or median (IQR)
Eur J Nucl Med Mol Imaging
accuracy are shown in Table 2. A positive SN on histology
after SLNB was found in 14 patients (24.1%), 10 with
melanoma and 4 with breast cancer. Submicrometastases
were present in 5 of 14 patients (35.7%), 3 with melanoma
(<0.1 mm at any site or 0.4 mm subcapsular) and 2 with
breas t cancer (≤0.2 mm isola ted tumour cel l s ) .
Micrometastases were present in four patients (28.6%), 3
with melanoma (>0.1–1.0 mm) and 1 with breast cancer
(>0.2–2.0 mm). Macrometastases were present in the re-
maining five patients (35.7%), 4 with melanoma
(>1.0 mm) and 1 with breast cancer (>2.0 mm).
In the pilot phase of the study an additional CNB of the SN
was done in ten breast cancer patients. The biopsy was not
representative in four patients due to collection of an insuffi-
cient amount of tissue. Histology after SLNB revealed a
macrometastasis in one patient.
Table 2 Measures of diagnostic
accuracy of US examination,
FNAC and core needle biopsy
Results, n (%)
FNAC (n = 58) US examination (n = 58)a CNB (n = 10)
True positive 0 2 (3) 0
Tumour
Breast cancer n/a 1 (50) n/a
Melanoma n/a 1 (50) n/a
SN location
Axilla n/a 1 (50) n/a
Groin n/a 1 (50) n/a
False positive 1 (2) 6 (10) 0
Tumour
Breast cancer 0 2 (33) n/a
Melanoma 1 (100) 4 (66) n/a
SN location
Axilla 1 (100) 6 (100) n/a
Groin 0 0 n/a
True negative 43 (74) 38 (66) 9 (90)
Tumour
Breast cancer 17 (40) 15 (40) 9 (100)
Melanoma 26 (61) 23 (61) 0
SN location
Axilla 36 (80)b 29 (76) 9 (100)
Groin 9 (20) 9 (24) 0
False negative 14 (24) 12 (21) 1 (10)
Tumour
Breast cancer 4 (29) 3 (25) 1 (100)
Melanoma 10 (71) 9 (75) 0
SN location
Axilla 6 (43) 5 (42) 1 (100)
Groin 8 (57) 7 (58) 0
Measures, % (95% CI)
Sensitivity 0 14 (3–38) 0
Specificity 98 (90–100) 86 (74–94) 100
Positive predictive value 0 25 (5 – 59) 0
Negative predictive value 75 (63–85) 76 (63–86) 90 (63–99)
CI confidence interval, CNB core needle biopsy, FNAC fine needle aspiration cytology, n/a not applicable, US
ultrasound
aAccording to the Berlin criteria, a malignant/suspicious sentinel node on US examination was recorded as
positive
b Two patients had SNs identified in the groin and axilla
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Discussion
The pilot phase of this prospective trial showed that gamma
probe-guided US can accurately identify the SN in up to 90%
of patients. This is in line with previous reported correct iden-
tification rates of 75–100% [13–16]. Furthermore, at least 75%
of the FNAC samples had a radioactivity signal more than
twice the background signal, which supports the high accuracy
of SN identification. However, FNAC lacked sensitivity as it
was not able to correctly detect metastases in the SN.
A high body mass index, a high background signal, the
presence of a cluster of multiple nodes and a presumed SN
location close to the injection site might hamper SN visuali-
zation and identification. In the present study, accurate radio-
graphic SN visualization and identification was impossible in
10 of 68 patients (15%). This was predominantly caused by a
low transcutaneous radioactivity signal, presumably as a result
of poor tracer uptake or tracer migration. SLNB was success-
ful in all ten patients and in at least two patients the signal was
also recorded as low during the surgical procedure.
All 51 patients (88%) with representative cytological
smears stained with H&E showed normal cytomorphology.
Additional cytomorphology and immunohistochemistry anal-
ysis on Cellient blocks was possible in 39 patients (67%). One
of these patients showed abnormal morphology with positive
immunohistochemistry in the Cellient block, and was record-
ed as having a positive FNAC. However, on histology the
SLNB turned out to be negative, even after additional slides
had been reviewed. Thus, this FNAC was recorded as false-
positive. In 15 patients (39%) the H&E-stained smears and
Cellient blocks showed normal morphology but a non-
specific immunohistochemistry. The FNAC in these patients
was regarded and recorded as negative. Remarkably, histology
after SLNB showedmetastasis in 6 of these 15 patients (40%).
The Mini 900 scintillation monitor with a sodium iodide
crystal was used on 44 samples, and showed a signal more
than twice the background signal in 75% of the samples.
This supports the high accuracy of SN identification using
FNACwith gamma probe andUS guidance, as was previously
demonstrated in the trial phase with a correct identification rate
of 90% [12]. A signal equal to or lower than the background
count does not necessarily mean that the sample is not radio-
active, but could be a result of a higher background count that
occurs occasionally or a low sample volume. Sowith respect to
the false-positive FNAC, the degree of certainty that the lymph
node from which FNAC was done was similar to the excised
lymph node is at least 75% tending towards 90%. Fusion ofUS
guidance with free-hand SPECT connected to a gamma detec-
tion device might become an alternative method that could
further increase the correct identification rate of the SN [21].
The FNAC technique would be considered successful
when a sensitivity of 90% was achieved. This was based on
the assumption that submicrometastases in melanoma (i.e.
<0.1mm at any site or 0.4 mm subcapsular) or isolated tumour
cells in breast cancer (i.e. <0.2 mm) are less likely to be de-
tected using FNAC and occur in approximately 10% of pa-
tients. Though our hypothesis for detecting positive SNs using
FNACwith combined gamma probe and US guidance seemed
promising, unfortunately the technique failed, as
micrometastatic and also macrometastatic lesions were not
detected. This failure can partially be explained by the rela-
tively small sizes of the metastatic lesions in the SN in nine of
14 patients (<1.0 mm for melanoma and <2.0 mm for breast
cancer) and in five of these patients the lesions were even
submicrometastases. The histological pattern of a subcapsular
metastasis is often small and spread in line with the capsule,
thus presenting the physician performing the FNAC with a
great challenge since it is easy to puncture through the lesion
into the parenchyma [22]. On the other hand, a detection limit
(the smallest diameter of SN melanoma metastasis that can be
detected) for a positive FNAC of 0.3 mm has been reported
[23]. This suggests that the detection of micrometastases, and
certainly macrometastases, should be possible.
In the previous promising studies on US-guided FNAC
almost all procedures were performed by the same senior
sonologist who usually obtained four cortical samples per
SN [18, 19, 22, 23]. In our study the procedure was per-
formed by several dedicated radiologists with usually one
or two cortical samples per SN. Thus, operator dependency
and fewer cortical samples per SN (which increases the
chance of missing smaller areas of interest within the SN)
might also be possible explanations for our results. In this
light, the use of large-lumen needles (10-gauge or 12-
gauge) might increase the effectiveness of the procedure in
detecting metastasis [24]. However, we performed CNB
using a 14-gauge needle in ten patients in the pilot phase,
and of these patients one turned out to havemacrometastasis
in the SN which was not detected by CNB. This suggests
that piecemeal sampling, regardless of the needle lumen,
compromises pathological evaluation. Technical difficul-
ties could also have contributed (e.g. small node, difficult
location and/or recognition of the presumed SN, blood in
the SN after the first sample). This illustrates the difficulty
in the broad implementation of the technique. It is notewor-
thy that in most previous studies investigating the sensitiv-
ity of US-guided FNAC, FNACwas performed only if there
was suspicion of metastasis on US examination [12]. This
increases the likelihood of a positive FNAC considerably
and explains some of the higher reported sensitivity rates,
and might explain our sensitivity rate since we performed
FNAC regardless of suspicion of metastasis on US exami-
nation. Nonetheless, low sensitivity and moderate negative
predictive values remain an issue [25].
Our study clearly had some limitations mainly due to the
premature termination of the trial. This naturally resulted in a
smaller number of included patients than initially planned.
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Nevertheless, it represents prospectively collected data and the
interim analysis showed that even in the best case scenario it
would have been impossible to achieve the desired sensitivity
of at least 80%. Thus, continuation of the trial would not have
led to substantially different conclusions.
Although the main outcome of this trial was negative and
was not in accordance with our hypothesis, valuable informa-
tion was obtained. FNAC with gamma probe and US guid-
ance is not able to correctly detect metastases in the SN and
the technique used is therefore not able to replace the SLNB
procedure. On the other hand, gamma probe-guided US was
found to be highly accurate in correctly identifying the SN.
This offers possibilities for evaluating other minimally inva-
sive techniques that incorporate gamma probe-guided US for
SN identification.
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